|Articles|March 15, 2002
- BioPharm International-03-15-2002
- Volume 15
- Issue 3
Guest Editorial: Warning Letters ? A Symptom?
Author(s)Steven S. Kuwahara
by Steven S. Kuwahara, Titan Pharmaceuticals Numerous warning letters and consent decrees have revealed problems in coping with even simple parts of the GMPs.
Advertisement
Articles in this issue
over 23 years ago
Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?over 23 years ago
The Importance of Freezing on Lyophilization Cycle Developmentover 23 years ago
Business Benefits of Computer Systems Validationover 23 years ago
A System Developer's Approach to ValidationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
2
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
3
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
4
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
5
